Background:

Bencianol is a the semisynthetic flavinoid, with anti-spasmogenic activities.

Bencianol causes a dose-related (1-100 μg/mL) reversal of contractions induced by 5-hydroxytryptamine, nor-adrenaline, angiotensin II, prostaglandin F2a, and U-46619 (a thromboxane-A2 mimetic). Bencianol is more effective against contractions induced by EC50 compared to maximal concentrations of each agent, and is least effective against the thromboxane-A2 mimetic, U-46619[1]. Bencianol (0.1-100 nM) produces cytoprotective effects against CCl4 induced cell injury on the above three parameters[2].

[1]. Whalley ET, et al. Anti-spasmogenic effects of bencianol (ZY15051) on human cerebral arteries in vitro. Cephalalgia. 1985 Dec;5(4):217-21. [2]. Maignan MF, et al. Cytoprotective effects of Bencianol on porcine vascular endothelial cells in vitro. J Submicrosc Cytol. 1986 Jan;18(1):47-51.